Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Peripheral neuropathic pain
- Score of at least 40 mm on the VAS of the SF-MPQ at screening and baseline
- Completion of at least 4 daily pain diary entries with an average daily pain score of at least 4 over the 7 days prior to baseline
- Exclusion criteria:
- (none)
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00631943
Start Date
November 1 2004
End Date
March 1 2005
Last Update
January 22 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bangalore, Karnataka, India, 560054
2
Pfizer Investigational Site
Bangalore, Karnataka / India, India, 560 034
3
Pfizer Investigational Site
Mumbai, Maharashtra, India, 400 012
4
Pfizer Investigational Site
Maharashtra, Mumbai, India, 400 007